Combination of deoxypodophyllin and 5-fluorouracil and its preparation and use

A kind of technology of deoxypodophyllin and fluorouracil, which is applied in the field of compound preparation, the combination of deoxypodophyllin and 5-fluorouracil

Inactive Publication Date: 2011-11-30
LANZHOU UNIVERSITY
View PDF4 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

It can be seen that the overall performance of podophyllotoxin compounds has good biological activity, but different compounds may have different mechan...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combination of deoxypodophyllin and 5-fluorouracil and its preparation and use
  • Combination of deoxypodophyllin and 5-fluorouracil and its preparation and use
  • Combination of deoxypodophyllin and 5-fluorouracil and its preparation and use

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] Preparation of N-5-fluorouracil acetic acid 4′-nor-4-deoxypodophyllotoxin ester

[0024] Take 77 mg (0.2 mmol) of the compound of formula III and dissolve it in 10 ml of dry dichloromethane, add N-5-fluorouracil acetic acid (40 mg, 0.22 mmol) and a catalytic amount of N, N-dimethylaminopyridine at room temperature under nitrogen protection, Stirring was continued until the reaction was completed. The white solid compound was separated by direct column chromatography. The detection data of the product obtained by the reaction are as follows:

[0025] Yield: 62%; m.p.: 180-182°C; (c 0.3, CHCl 3 ); IR (cm -1 ) 3194, 3072, 3004, 2943, 2915, 2844, 1773, 1706, 1670, 1601, 1505, 1483, 1463, 1420, 1378, 1337, 1227, 1159, 1130, 1093, 1037, 996; 1 HNMR (400MHz, CDCl 3 )δ9.40(br, 1H, NH), 7.31(d, J=5.6Hz, 1H), 6.67(s, 1H), 6.51(s, 1H), 6.39(s, 2H), 5.95(d, J =7.6Hz, 2H), 4.77(s, 2H), 4.63(d, J=4.4Hz, 1H), 4.46(t, J=8.8Hz, 1H), 3.92(t, J=8.8Hz, 1H), 3.70(s, 6H, 2OMe), 3.07...

Embodiment 2

[0028] Preparation of N-5-fluorouracil acetyl-L-alanine 4′-nor-4-deoxypodophyllotoxin ester

[0029] The experimental procedure is the same as in Example 1, except that N-5-fluorouracil acetyl-alanine is used instead of N-5-fluorouracil acetic acid. The detection data of the product obtained by the reaction are as follows:

[0030] Yield: 70%; m.p.: 168-170°C; (c 0.3, CHCl 3 ); IR (cm -1 )3518, 3316, 3206, 3071, 2920, 2846, 1768, 1696, 1670, 1601, 1505, 1483, 1462, 1422, 1379, 1338, 1227, 1130, 1037, 996; 1 HNMR (400MHz, CDCl 3 )δ9.71 (brs, 1H, NH), 7.36-7.33 (m, 1H, NH), 7.17 (d, J=7.2Hz, 1H), 6.66 (s, 1H), 6.49 (s, 1H), 6.37 (s, 2H), 5.93(d, J=7.6Hz, 2H), 4.88-4.83(m, 1H), 4.60(d, J=4.0Hz, 1H), 4.45(t, J=6.4Hz, 1H) , 4.36-4.33(m, 2H), 3.90(t, J=8.8Hz, 1H), 3.66(s, 6H, 2OMe), 3.06(dd, J=12.0, 4.0Hz, 1H), 2.80-2.72(m , 3H), 1.55(d, J=7.2Hz, 3H); 13 C NMR (100MHz, CDCl 3 ( d, J=33Hz, 1C), 128.4, 127.2, 110.3, 108.5, 107.8, 101.2, 72.1, 56.2 (2OMe), 49.9, 48.4, 47.2, ...

Embodiment 3

[0033] Preparation of N-5-fluorouracil acetyl-L-valine 4-deoxy-4′-norpodophyllotoxin ester

[0034] The experimental procedure is the same as in Example 1, except that N-5-fluorouracil acetyl-valine is used instead of N-5-fluorouracil acetic acid. The detection data of the product obtained by the reaction are as follows:

[0035] Yield: 65%; m.p.: 183-185°C; (c 0.3, CHCl 3 ); IR (cm -1 )3316, 3204, 3070, 3002, 2966, 2938, 2844, 1765, 1703, 1601, 1505, 1483, 1465, 1422, 1378, 1338, 1227, 11154, 1131, 1038, 996; 1 H NMR (400MHz, CDCl 3 )δ7.35(d, J=5.6Hz, 1H), 7.05(br, 1H), 6.67(s, 1H), 6.50(s, 1H), 6.37(s, 2H), 5.94(d, J=3.2 Hz, 2H), 4.88-4.84(m, 1H), 4.61(d, J=3.2Hz, 1H), 4.46(t, J=6.8Hz, 1H), 4.36(q, J=3.6Hz, 2H), 3.90(t, J=8.8Hz, 1H), 3.66(s, 6H, 2OMe), 3.07(dd, J=13.2, 4.4Hz, 1H), 2.80-2.67(m, 3H), 2.46-2.35(m, 1H), 1.01(d, J=6.8Hz, 6H); 13 C NMR (100MHz, CDCl 3 )δ175.0, 174.9, 169.4, 166.2, 157.2 (d, J=27Hz, 1C), 151.1, 151.0, 149.9, 147.1, 146.7, 140.3 (d, J=236H...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses deoxypodophyllo and 5-fluorouracil spliced compounds, and a preparation method and application of the compounds. The structure of the deoxypodophyllo and 5-fluorouracil spliced compounds is shown as a formula I or II. The preparation method for the spliced compounds comprises the following steps of: mixing 4'-demethyl-4-deoxypodophyllo and 5-FUalkyl acyl-N-substituted amino acid or 5-FU substituted fatty acid, and reacting in the presence of a condensing agent of dicyclohexylcarbodiimide (DCC) and a catalyst of N,N-dimethyl-aminopyridine to obtain the target compounds shown as the formula. The deoxypodophyllo and 5-fluorouracil spliced compounds can be applied to preparing medicines for treating tumors.

Description

technical field [0001] The invention relates to an organic compound used for preparing medicine, a preparation method and application of the compound. Specifically, the present invention is a combination of deoxypodophyllin and 5-fluorouracil, as well as the preparation method and application of this compound. Background technique [0002] Podophyllotoxin (PT) and related lignans are a class of natural active substances with significant cytotoxicity. Its biological activities are mainly anti-tumor, anti-virus, etc., but due to its high toxicity, its direct use as a drug is limited. For this reason, a large number of structural modifications have been carried out on podophyllotoxin, and many active compounds have been obtained, among which Etoposide (VP-16) and Teniposide (VM-26) developed in the mid-1970s and Etopophos released in the mid-1990s (Prodrugs of VP-16) are used as clinical first-line anti-tumor drugs, and are widely used in small cell lung cancer, non-Hodget's ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07D493/04C07K5/078C07K1/10A61P35/00A61P35/02
Inventor 陈世武向蓉惠玲
Owner LANZHOU UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap